 LexaGene Holdings Inc OTCQB:LXXGF CVE:LXG said that it has successfully utilized its MiQLab System to detect the presence of mycoplasmas, a group of common microbial contaminants responsible for substantial losses in both time and money for biopharmaceutical manufacturers. In a statement, LexaGene founder CEO Dr Jack Regan said: We are increasingly harnessing the power of our MiQLab to drastically shorten the time-to-result for microbial biopharmaceutical contamination detection. 